NASDAQ$VERA
Vera Therapeutics Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Vera Therapeutics reported business highlights for the fourth quarter and financial results for the full year ended December 31, 2022
Vera Therapeutics reported a net loss of $89.1 million for the year ended December 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $114.7 million as of December 31, 2022. They are prioritizing advancement of atacicept in IgAN, plans to initiate Phase 3 clinical trial in second quarter of 2023
- Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeks
- 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on track for the second quarter of 2023
- Management prioritizing advancement of atacicept in IgAN, plans to initiate Phase 3 clinical trial in second quarter of 2023
- Strong balance sheet expected to fund IgAN-focused operations to early 2026
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$362K
Forward guidance
Vera Therapeutics plans to advance atacicept into pivotal Phase 3 development in the second quarter of 2023, expects to report Phase 3 topline data at Week 36 and ongoing data from the ORIGIN trial in 2023, and plans to prioritize and focus current resources on the advancement of atacicept in IgAN into a pivotal Phase 3 trial.
Tailwinds
- Atacicept’s potential to be a transformational treatment for patients with IgAN and a best-in-disease therapy
- Plans to advance atacicept into pivotal Phase 3 development in the second quarter of 2023
- Expectations regarding reporting Phase 3 topline data at Week 36 and ongoing data from the ORIGIN trial in 2023
- Plans to prioritize and focus current resources on the advancement of atacicept in IgAN into a pivotal Phase 3 trial
- Vera’s product candidates, strategy, and regulatory matters
Headwinds
- Risks related to the regulatory approval process
- Results of earlier clinical trials may not be obtained in later clinical trials
- Risks and uncertainties associated with Vera’s business in general
- The impact of the COVID-19 pandemic
- Other risks described in Vera’s filings with the Securities and Exchange Commission
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2022
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro